**Appendix 3 – scenario analysis**

**Table A1.** Outcomes of scenario 1 in which a modified SPLASH regimen for 177Lu-PSMA-I&T is used

|  |  |  |
| --- | --- | --- |
|  | **Radium-223** | **177Lu-PSMA-I&T** |
|  | **ALSYMPCA regimen** | **Modified SPLASH regimena** |
| *Medication* | €26,796 | €23,256 |
| *Administration* | €1,559 | €779 |
| *Hospital admission* | €393 | €196 |
| *Observation* | N/A | €400 |
| *Supportive care* | €926 | €954 |
| *Monitoring* | €612 | €306 |
| *Imaging* | €619 | €1,328 |
| **Total costs** | €30,905 | €27,221 |
| **Total coverage** | €34,806 | €23,700 |
| **Difference** | €3,901 | -€3,521 |

**Note:** a The modified SPLASH regimen consisted of three 8-weekly injections of 6.8 GBq.  
**Abbreviations**: 177Lu-PSMA-I&T: Lutetium-177-labelled- prostate-specific membrane antigen imaging and treatment

**Figure A1.** Difference between per-patient costs and coverage calculated per DBC value and break-even value for each regimen included in the model and the modified SPLASH regimen  
**Note:** The modified SPLASH regimen consisted of three 8-weekly injections of 6.8 GBq.  
**Abbreviations:** DBC: Diagnosis treatment combination; 177Lu-PSMA-I&T: Lutetium-177-labelled- prostate-specific membrane antigen imaging and treatment